Boehringer Ingelheim reported 2024 financial results, with group net sales rising 7.3% YoY to EUR 27.8 billion (USD 32.2 billion), driven by Human Pharma and Animal Health business momentum. R&D investment surged to EUR 6.4 billion (22.9% of sales), underscoring the family-owned company’s long-term innovation commitment. The Human Pharma division grew 7.4% to EUR 22.7 billion, led by Jardiance (empagliflozin) sales jumping 8.7% to EUR 8.8 billion, while 2025 launches of Hernexeos (zongertinib) and Jascayd (nerandomilast) expanded the portfolio.
Competitive Positioning: Private ownership enables $6.4B R&D bet on CRM + oncology while peers face margin pressure; Jardiance + Ofev cash cows fund innovation
Forward‑Looking Statements This brief contains forward‑looking statements regarding 2025 launch performance, pipeline progression, and Jardiance market expansion. Actual results may differ due to competitive dynamics with SGLT2/GLP-1 combinations, regulatory review timelines for pipeline assets, and Animal Health market volatility.-Fineline Info & Tech
